Even if Nivolumab, an antibody targeting PD-1, has recently received Food and Drug Administration (FDA) approval for NSCLC therapy, regardless of the PDL1 expression status, a better prediction of which patients are more likely to respond to this cancer therapy may improve the treatment costs. The gene discussed is PDCD1; the disease is cancer.